More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$29.92B
EPS
3.66
P/E ratio
15.3
Price to sales
2.49
Dividend yield
4.176%
Beta
0.855584
Previous close
$56.30
Today's open
$56.57
Day's range
$56.24 - $57.02
52 week range
$33.65 - $64.60
show more
CEO
Gabriel Podskubka
Employees
29134
Headquarters
Luxembourg,
Exchange
New York Stock Exchange
Shares outstanding
529450331
Issue type
American Depository Receipt
Energy
Fossil Fuels
Tenaris: Q2 Earnings Don't Make The Upside Any Better, Maintain Hold
Tenaris is rated 'HOLD' with a price target of €16/share ($36.91 ADR), reflecting cyclical risks and recent overvaluation. TS faces near-term headwinds from Hormuz shipment delays, margin compression, and declining revenues, signaling a mid-cycle to early downcycle transition. While TS maintains a strong balance sheet and leading market position, its earnings power remains tightly linked to volatile energy CapEx cycles.
Seeking Alpha • Aug 12, 2026

Tenaris Q2 Earnings Call Highlights
Tenaris NYSE: TS reported second-quarter sales of $3 billion, down 4% from both a year earlier and the prior quarter, as shipping disruptions in the Middle East delayed deliveries to customers in Iraq, Kuwait and Qatar.
MarketBeat • Aug 9, 2026

Tenaris S.A. (TS) Q2 2026 Earnings Call Transcript
Tenaris S.A. (TS) Q2 2026 Earnings Call Transcript
Seeking Alpha • Aug 6, 2026

Tenaris Announces 2026 Second Quarter Results
The financial and operational information contained in this press release is based on unaudited consolidated condensed interim financial statements presented in U.S. dollars and prepared in accordance with IFRS Accounting Standards as issued by the International Accounting Standard Board and adopted by the European Union, or IFRS. Additionally, this press release includes non-IFRS alternative performance measures i.e., EBITDA, Free Cash Flow, Net cash / debt and Operating working capital days. See exhibit I for more details on these alternative performance measures.
GlobeNewsWire • Aug 5, 2026

Compared to Estimates, Tenaris (TS) Q2 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Tenaris (TS) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Zacks Investment Research • Aug 6, 2026

5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% (August 2026)
This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering significant discounts to their historical norms. We go over our filtering process to select just five conservative DGI stocks from more than 7,500 companies that are traded on U.S. exchanges, including OTC networks. In addition to the primary list that yields 4.2%, we present two other groups of five DGI stocks each, from moderate to high yields of up to 8%.
Seeking Alpha • Aug 5, 2026

Why Tenaris S.A. (TS) is a Great Dividend Stock Right Now
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Tenaris (TS) have what it takes?
Zacks Investment Research • Aug 3, 2026

Tenaris S.A. (TS) Could Be a Great Choice
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Tenaris (TS) have what it takes?
Zacks Investment Research • Jul 15, 2026

NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome
Toronto, Ontario – TheNewswire - July 15, 2026 – NeuroThera Labs Inc. (TSXV: NTLX) (the " Company " or " NeuroThera "), a clinical-stage biotech company and a majority-owned subsidiary of SciSparc Ltd. (Nasdaq: SPRC), today announced the initiation of its Phase IIb clinical trial site at Hannover Medical School, Hanover (“MHH”), Germany, for SCI-110, its proprietary cannabinoid-based treatment candidate for Tourette Syndrome (TS) in adults. The trial, which previously received regulatory clearance from Germany's Federal Institute for Drugs and Medical Devices and MHH's ethics committee , is now advancing towards the next stage at Hannover Medical School, one of the key clinical sites of the study. SCI-110 combines dronabinol with the endocannabinoid-like palmitoylethanolamide in an innovative one dosage form designed to reduce tics and comorbid symptoms in adults with TS while minimizing side effects.

5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% (July 2026)
This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering significant discounts to their historical norms. We go over our filtering process to select just five conservative DGI stocks from more than 7,500 companies that are traded on U.S. exchanges, including OTC networks. In addition to the primary list that yields 4.1%, we present two other groups of five DGI stocks each, from moderate to high yields of up to 8%.
Seeking Alpha • Jul 11, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Tenaris S.A. American Depositary Shares commission-free¹. Build wealth for the long term using automated trading and transfers.